Caspase 9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Caspase-9 is encoded by the CASP9 gene. It is a Caspase family, initiator caspases involved in caspase-9 is the initiator caspase of the intrinsic apoptotic pathway. it is activated by the apopto... [1]
| Caspase-9 | |
|---|---|
| Protein Name | Caspase-9 |
| Gene | [CASP9](/genes/casp9) |
| UniProt ID | [P55211](https://www.uniprot.org/uniprot/P55211) |
| PDB ID(s) | 1JXQ, 1KZX, 1KZY, 2J9O, 3MS3, 3MS4, 4JXU |
| Molecular Weight | 46.6 kDa |
| Subcellular Localization | Mitochondria, Cytoplasm |
| Protein Family | Caspase family, initiator caspases |
Caspase-9 is synthesized as an inactive proenzyme (46 kDa) with an N-terminal prodomain. Upon activation, it forms a tetramer with two catalytic subunits.
Caspase-9 is the initiator caspase of the intrinsic apoptotic pathway. It is activated by the apoptosome (Apaf-1 + cytochrome c) and then cleaves and activates executioner caspases-3, -6, and -7. Caspase-9 activity is regulated by Bcl-2 family proteins and inhibitor of apoptosis proteins (IAPs).
Mitochondrial dysfunction leads to cytochrome c release and apoptosome activation, triggering caspase-9 cascade.
Caspase-9 is activated in dopaminergic neurons following mitochondrial Complex I inhibition and PINK1/Parkin pathway dysfunction.
Ischemic injury triggers mitochondrial permeabilization and caspase-9 mediated neuronal death.
Secondary injury involves mitochondrial dysfunction and caspase-9 activation.
Caspase-9 specific inhibitors (LEHD-FMK) are being studied for neuroprotection in stroke and traumatic brain injury.
Caspase-9 is activated through the intrinsic (mitochondrial) apoptotic pathway:
Caspase-9 is regulated by:
Caspase-9 activation varies across brain regions:
Caspase-9 activation can be measured:
The study of Caspase 9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.